1. Seminar On
MICROENCAPSULATION AND MDDS
1/53
By:Rajesh L. Dumpala
(B.Pharm, M. Pharm.) PhD. ( Pursuing)
Research Scientist,
Alembic Research Centre. Vadodara
E.Mail:-rdumpala64@gmail.com
2. Contents:
Introduction
Methods for microencapsulation
Characterization and evaluation
Drug release measurement
Applications
Recent advances
2/53
4. What is Microcapsule &
Microsphere?
Encapsulation involves surrounding drug molecules with a
solid polymer shell
Entrapment involves the suspension of drug molecules
within a polymer matrix.
drug
polymer
Drug
Polymer
4/53
5. Selection of a coating material:
Objectives of the dosage form or
product requirements.
Identifying and selecting the coating
material which will satisfy these product
requirements.
Microencapsulation method used to
accomplish the coated product
requirements.
5/53
6. Ideal requirements of a coating
material:
Capable of forming a cohesive film with
the core material.
Chemically compatible and non reactive
with the core material.
Provide the desired coating properties,
like, strength, flexibility, impermeability,
optical properties and stability.
6/53
13. Limitations of coacervate microcapsules:
Produced only at specific pH values.
Toxicity problems.
Addition of chemical cross linking agents and
application of heat are harmful to the encapsulant
materials, such as thermo and chemically labile drugs
and live cells.
13/53
18. Principal mononer combinations investigated for the
encapsulation of pharmaceuticals by polymerization:
Aqueous phase
monomer A
Non-aqueous phase
monomer B
Poly AB wall material
found
Polyamine:
e.g. L-lysine
Polybasic acid halide
Sebacoyl chloride,
Terephthaloyl chloride
Polyamide,
Nylon 6-10,
Polyterephthalamide
Polyphenol:
e.g. 2,2-bis(4-
hydroxyphenyl) propane
Polybasic acid halide
Sebacoyl chloride
Polyester
Polyphenyl ester
Polyamide:
e.g. 1,6- hexamethylene
diamide
Bischloroformate
2,2-dichloro diethyl ether
Polyurethrane
Polyurethrane
18/53
19. In situ polymerization:
No reactive agents are added to the
core agent.
Process:
1. Polymerization of monomers into low
mol. wt. Prepolymer.
2. Formation of solid capsule shell by
polymerization and cross linking.
19/53
24. Representative coating materials and applicable microencapsulation
process:
Coating materials Multiorifice
centrifugal
Coacervation
phase
separation
Pan
coating
Spray drying
and
congealing
Air
suspension
Solvent
evaporation
Water soluble resins:
Gelatin
X X X X X X
Gum arabic X X X X X
Starch X X X X
PVP X X X X X
CMC X X X X
HEC X X X X X
MC X X X X
Arabinogalactan X X X X
PVA X X X X X X
Polyacrylic acid X X X X X
Water insoluble resins:
E.C.
X X X X X
Polyethylene X X X
Polymethacrylate X X X X X
Polyamide X X
Poly (ethylene-vinyl-acetate) X X X X X
Cellulose nitrate X X X X X
Silicones X X
Poly (lactide-co-glycolide) X X X
24/53
25. Coating
materials
Multiorifice
centrifugal
Coacervatio
n phase
separation
Pan coating Spray
drying and
congealing
Air
suspension
Solvent
evaporation
Waxes and
lipids:
Paraffin
X X X X X
Carnauba X X X
Spermaceti X X X X
Bees wax
stearic acid
X X X
Stearyl
alcohol
X X
Glyceryl
stearate
X X X
Enteric
resins:
Shellac
X X X X
CAP X X X X X
Zein X X
25/53
26. Microencapsulation processes and their
applicabilities:
Microencapsulation
process
Applicable core
material
Approximate particle
size(μm)
Air suspension solids 35-5000
Coacervation phase
separation
Solids and liquids 2-5000
Multiorifice centrifugal Solids and liquids 1-5000
Pan coating solids 600-5000
Solvent evaporation Solids and liquids 5-5000
Spray drying and
congealing
Solids and liquids 600
26/53
27. Drug loading
Total mass of
drug and polymer
Ratio of dispersed
to continuous phase
Ratio of drug
To polymer
Mol. Wt. of
The polymer
Particle size
and
P.S.D.
Manufacturing
variables
27/53
39. Conc. Gradient
existing across the
coating membrane
Coating thickness
Permselectivity of
coating to
core material
Permeability of
coating to
the extraction fluid
Dissolution rate
of core material
Factors
affecting
Drug release
39/53
41. To control
The release
Organ targeting
Passive, Active,
Diversional,
physical
Bioavailability
improvement
Separation of
Incompatible
substances
Handling of
Toxic materials
Ease of
handling
Taste
masking
Protection
Of reactive
materials
Applications
41/53
42. APPLICATIONS OF MICROENCAPSULATION:
Core material Characteristic properties Purpose of
encapsulation
Final product form
Acetaminophen Slightly water soluble solid Taste masking Tablet
Activated charcoal Adsorbent Selective sorption Dry powder
Aspirin Slightly water soluble solid Taste masking, sustained
release, reduced gastric
irritation
Tablet or capsule
Islet of langerhans Viable cells Sustained normalization
of diabetic condition
Injectable
Isosorbide
dinitrate
water soluble solid Sustained release Capsule
Liquid crystals Liquid Conversion of liquid to
solid, stabilization
Flexible film for thermal
mapping of anatomy
Methanol/methyl
salicylate camphor
mixture
Volatile solution Raduction of volatility Lotion
Projesterone Slightly water soluble solid Sustained release Varied
KCl Highly water soluble solid Reduced gastric irritation capsule
Urease water soluble enzyme Permselectivity of
enzyme, substrate, and
reaction products
dispersion
Vit. A palmitate Nonvolatile liquid Stabilization to oxidation Dry powder
42/53
43. Research work (recent):
Encapsulation of DNA in
nanoengineered polymer(disulfide cross
linked poly(methacrylic acid))
microcapsules.- 284707n
Preparation of floating microspheres of
Eudragit E 1oo for fish farming by
solvent evaporation method of
josamycin.-248781g
CA- sept-24, vol 147, no. 13, 2007
43/53
44. Vol. 146, no. 23, June-4, 2007:
Microcapsule gel formulation of Promethazine HCl for controlled nasal
delivery.(468224p)
Microcapsules comprising active ingredients and isopropylamide(467920a)
Combining electrochemistry and high resolution microscopy to trigger and
monitor release process from individual polymeric microspheres(468095x)
Polyelectrolyte assembling for protein microencapsulation(468170t)
Cartilage regeneration using a novel gelatin-chondroitin-hyaluronal hybrid
scaffold containing bFGF- impregnated microspheres.(468404x)
Phagocytosis of poly(L-lysine)- graft-PEG coated microspheres by antigen
presenting cells.(468189f)
Multilayer coated microspheres containing pancreatin and pepsin and other
digestive enzymes.(468498f)
Decrease in protein aggregation on oil-water interface by pluronic F
127.(79222j)
Colon targeting of carboxy methyl chitosan microspheres containing
levofloxacin.(79161p)
44/53
45. Research work done:
DRUGS COATING MATERIAL METHOD
Adriamycin E.C. Coacervation
Ascorbic acid E.C., E.C.+CAP, PEG 6000 Coacervation, pan coating
Aspirin E.C., E.C.+CAP,Eudragit E Coacervation
Bitolterol mesylate E.C. Coacervation
Caffeine E.C.+PEG 4000 Fluid bed coating
Carbaquone E.C. Coacervation
Chloramphenicol E.C., Na-alginate, CAP Coacervation
Clofibrate Gelatin Coacervation
Dexamethasone E.C., Gelatin Coacervation
Flufenamic acid Acrylic resin Fluid bed coating
Hemoglobin E.C. Coacervation
45/53
49. Research work on mucoadhesive microspheres
and microcapsules:
drug polymer route
acyclovir chitosan ocular
Methyl prednisolone Hyaluronic acid ocular
Gentamycin DSM+LPC nasal
Insulin DSM+LPC nasal
Human growth hormone DSM+LPC Nasal
desmopressin Starch Nasal
beclomethasone HPC Nasal
gentamycin chitosan Nasal
amoxycillin carbopol GI
vancomycin PGEF coated with
Eudragit S 100
colonic
insulin HYAFF vaginal
50. References:
Encyclopedia of pharmaceutical Technology.10,1-29.
Controlled drug delivery- by J.R. Robinson.
The theory and practice of industrial pharmacy- by Leon
Lachman.
Sustained release injectable products- by Michael L.
Randomsky, Judy H. Senior
‘M. Pharm’ thesis of Archana Surati August 2000.
‘Microencapsulation’, by Simon benita, Marcel Dekkar
publications
J Pharm Sci 93(4) 831-837.
J Pharm Sci 93(4) 943-955.
J Pharm Sci 93(5) 1100-1109.
J Pharm Sci 93(10) 2573-2584.
J Pharm Sci 93(10) 2624-2634.
50/53